Free Trial

Elekta AB (publ) (OTCMKTS:EKTAY) Reaches New 1-Year Low - What's Next?

Elekta AB (publ) logo with Medical background

Elekta AB (publ) (OTCMKTS:EKTAY - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $4.50 and last traded at $4.54, with a volume of 46422 shares traded. The stock had previously closed at $4.73.

Analyst Ratings Changes

Separately, Sanford C. Bernstein upgraded Elekta AB (publ) from a "strong sell" rating to a "hold" rating in a research report on Wednesday, January 29th.

Read Our Latest Stock Report on EKTAY

Elekta AB (publ) Trading Up 3.0 %

The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of 19.16 and a beta of 1.20. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.81 and a current ratio of 1.05. The business has a fifty day moving average price of $5.50 and a 200 day moving average price of $5.79.

Elekta AB (publ) (OTCMKTS:EKTAY - Get Free Report) last released its quarterly earnings data on Friday, February 21st. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). The company had revenue of $416.86 million during the quarter, compared to analysts' expectations of $435.89 million. Elekta AB (publ) had a net margin of 5.65% and a return on equity of 11.07%. As a group, equities analysts forecast that Elekta AB will post 0.36 earnings per share for the current year.

Elekta AB (publ) Cuts Dividend

The company also recently declared a dividend, which was paid on Thursday, March 27th. Stockholders of record on Friday, March 7th were issued a $0.1072 dividend. The ex-dividend date of this dividend was Friday, March 7th. Elekta AB (publ)'s dividend payout ratio (DPR) is 44.00%.

Elekta AB (publ) Company Profile

(Get Free Report)

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.

Featured Stories

Should You Invest $1,000 in Elekta AB (publ) Right Now?

Before you consider Elekta AB (publ), you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elekta AB (publ) wasn't on the list.

While Elekta AB (publ) currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir’s Big Week Reveals a Rare Growth Story in a Shaky Market
Buy the Fear: 3 Down Stocks That Could 10x Your Profits
Congress Bought THESE Stocks as Tariffs Tanked the Market

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines